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The term scans without evidence of dopaminergic deficit (SWEDD) can be associated 
with any patient diagnosed at first with Parkinson’s disease but with a negative dopamine 
transporter-single photon emission computed tomography (DaTSPECT), which does 
not confirm the presynaptic dopaminergic deficiency. Therefore, an alternative diagnosis 
should be sought to support parkinsonism as a clinical diagnosis. Parkinsonism is a 
well-known manifestation of frontotemporal lobar degeneration (FTLD), particularly fre-
quent in those with positive DaTSPECT. Here, we reinforce previous observations that 
parkinsonism can be present in FTLD patients with negative DaTSPECT and therefore, 
FTLD may account for a percentage of patients with SWEDD. We gather the clinical 
observations supporting this hypothesis and describe a case report illustrating this idea. 
Studies suggest the result of DaTSPECT in FTLD may depend on the neuropathology 
and clinical subtype. However, most studies do not provide a clinical description of the 
clinical subtype or pathological features making the association between subtypes of 
FTLD and DaTSPECT results impossible at the moment. Further studies correlating 
clinical, neuropsychological, neuroimaging, genetic, and pathology findings are needed 
to better understand parkinsonism in FTLD.
Keywords: scans without evidence of dopaminergic deficit, parkinsonism, dopamine transporter-single, photon 
emission computed tomography, presynaptic dopaminergic deficiency, frontotemporal lobar degeneration
introdUCtion
Parkinson’s disease (PD) is a common neurodegenerative disorder. It is characterized by progressive 
degeneration of dopaminergic neurons in the pars compacta of the substantia nigra and the loss 
of nerve terminals in the basal ganglia structures (1, 2). The dopaminergic system is one of the 
most studied neurochemical systems because damage to nigrostriatal neurons is the most critical 
component in the pathophysiology of PD (1, 3). Clinically it is manifested by the so-called “parkin-
sonian syndrome,” consisting of extrapyramidal signs, including bradykinesia and at least one of the 
following: 4–6 Hz rest tremor, muscular rigidity and postural instability. The term “parkinsonism” 
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encompass some nosologic entities, besides PD, which are 
grouped by their shared clinical features but are separated by their 
different pathologies.
The role of nigrostriatal dopamine deficits in PD has been firmly 
established (4–6). In recent years, dopamine transporter-single 
photon emission computed tomography, named DaTSPECT, has 
been used to detect degeneration of presynaptic dopamine recep-
tors in the nigrostriatal structures (6, 7). The active ingredient 
of [123I]FP-CIT SPECT is a cocaine analog, 123I-nortropane, 
labeled: N-u-fluoropropyl 2b-carbomethoxy-3b-(4-iodophenyl), 
also referred to as: ([123I]ioflupane). It binds to striatal presy-
naptic dopamine transporter (DaT) in animals and humans 
and helps visualize indirectly these neurons with SPECT. DaT 
is located on the plasma membrane, mainly of nerve terminals 
of dopaminergic neurons in the brain, particularly in the globus 
pallidus, cingulate cortex, amygdala, olfactory tubercle, and 
midbrain but specially in the striatum and nucleus accumbens. 
DaT reuptakes dopamine from the synaptic cleft into presynaptic 
neurons playing an important role in the buffering of this neu-
rotransmitter (8).
Baseline DaT imaging has a very high negative predictive 
value for degenerative conditions affecting the nigrostriatal 
pathway. Only a negligible proportion of normal dopaminergic 
SPECT can be found in atypical parkinsonisms (9). The acronym 
SWEDDs (scans without evidence of dopaminergic deficits) (10), 
arose from the clinical trial literature of PD, in which patients 
were imaged with 18F-dopa PET or DaTSPECT to monitor 
disease progression, revealing that a substantial proportion of 
clinically diagnosed cases of PD had regular nuclear medicine 
scans (4–15%) and were, therefore, designated as SWEDDs 
(10, 11). Thus, the term SWEDDs can be associated with any 
patient diagnosed at first with PD but in which subsequent 
functional imaging did not confirm the presynaptic dopamin-
ergic deficiency, although the use of the term SWEDD is itself 
controversial (9, 12).
The true etiology of the symptoms experienced by patients 
with SWEDD remains controversial, and it has been suggested 
that these individuals may represent a non-PD related move-
ment disorder (10, 13, 14). When patients with SWEDD were 
initially discovered, it was hypothesized that they might be within 
a prodromal phase of PD (15). However, subsequent research 
has demonstrated significant differences between patients with 
dopamine-deficient scans and patients with SWEDD. Patients 
with SWEDD lack response to levodopa (16) and do not 
demonstrate deficits in olfaction as frequently as patients with 
dopamine-deficient PD (17). Patients with SWEDD also have 
more significant cardiovascular and thermoregulatory dysfunc-
tion, orthostatic hypotension, sleep disturbances, and higher 
frequencies of daytime sleepiness than dopamine-deficient PD 
patients (18, 19). Although, patients with SWEDD can present 
motor features similar to those which are dopamine-deficient 
(PD), previous longitudinal research suggests that patients with 
SWEDD do not demonstrate the progression of motor symptoms 
(20) and continue to have normal DaTSPECTs for up to 4 years 
after they are initially identified (19, 21, 22). In a 5-year follow-up 
study of 16 patients with SWEDD, only 2 patients demonstrated 
reduced dopamine uptake on DaTSPECTs, while 14 remained 
classified as SWEDD (11). These studies seem to indicate that 
individuals with SWEDD have a distinctly different disorder than 
dopamine-deficient PDs (14, 15, 18, 22). Moreover, patients with 
SWEDD and long-standing parkinsonism exhibit non-motor 
features that differ from those of patients with PD. SWEDD 
patients had worse mood and cardiovascular function and better 
olfactory function than PD patients, but remain similar to patients 
with SWEDD and alternative final diagnoses (19). In general, 
the term SWEDD is a useful approach for those patients with 
slow-progressing parkinsonism, with mild evolution compared 
with PD. Some frontotemporal lobar degeneration (FTLD) have 
parkinsonism and a mild clinical course, probably this subgroup 
could represent a minority percentage of SWEDD (23–26).
In a prospective study of our research group, 30 patients 
with hard-to-diagnose tremor and normal DaTSPECT were 
followed for 2 years (27). After the follow-up scan diagnosis was 
reached for 18 cases. The other 12 patients underwent a second 
DaTSPECT and were then followed for 12 additional months. 
After this, the clinical diagnosis was performed again. The final 
diagnoses included a list of different entities, including neurode-
generative and non-neurodegenerative disorders. However, for 
six patients diagnosis remained uncertain. Interestingly, these 
six patients developed cognitive impairment with outstanding 
frontal features. It was first speculated that although some 
patients with SWEDDs had, in fact, dystonic tremor or other 
well-known neurological conditions, it was conceivable that 
some patients might have suffered from a disorder that had not 
yet been described. It was speculated that some of these patients 
might have suffered a neurodegenerative process originated in 
the frontal cortex spreading to subcortical structures (versus the 
subcortical →  cortical process present in PD). In this article, 
we present a case report illustrating this possibility and discuss 
the clinical, neuropsychological, genetics, and neuroimaging 
findings supporting the observation that FTLD is behind some 
cases of SWEDD.
Case report
Written informed consent was obtained from the patient for the 
publication of this case report. She is a 70-year-old woman who 
worked as a childcare worker and is now retired. She used to drink 
30 g alcohol/day until 10 years ago and she still smokes 5 ciga-
rettes/day. She was diagnosed with depressive syndrome 10 years 
ago. Currently, she is on Trazodone 100 mg/day and Clonazepam 
0.5  mg/day. There are cases of PD (brothers) and depression 
(mother and maternal grandmother) among her family records.
She first visited neurology clinics 10 years ago with memory 
loss complaints. On that occasion, cognitive screening tests, 
blood tests, and CT scan were normal. Complaints were supposed 
to be in relation with a mood disorder, and no treatment was 
prescribed. She came again 5  years ago due to impairment of 
memory. She also complained about unbalanced gait, intentional 
tremor, and difficulty doing fine tasks. Caregivers referred social, 
behavioral changes, and personal care difficulties, even when she 
was still living on her own at that time.
Neurological examination showed hypomimia, mild rigidity 
in the four limbs, global bradykinesia, and unbalanced gait. There 
FigUre 1 | Neuroimaging findings in the reported case. (a) Follow-up MRI mild diffuse atrophy with more intense atrophy on the left frontal and temporal lobes 
and some small vessel lesions affecting periventricular and semioval white matter. (B) FDG-PET shows mild-to-severe hypometabolism on the left frontotemporal 
lobe junction and mild hypometabolism on the left fronto-basal, left anterior cingulum regions. (C) HMPAO SPECT shows bilateral but asymmetric hypoperfusion 
(more on the left side) on frontotemporal lobes. (d) Dopamine transporter-single, photon emission computed tomography was informed of the normal density 
ofpresynaptic dopaminergic uptakers. Some irregularities in the morphology of basal ganglia and increase of cortical uptake can be noted.
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was a mild and mixed (rest and action) tremor affecting the four 
limbs. Her Mini-Mental Status Examination reflected deficits 
in memory, while her performance on the Frontal Assessment 
Battery was notable for impairment in inhibiting automatic 
responses, verbal fluency, and Trail making tests A & B. She also 
demonstrated deficits in the memory and verbal fluency sections 
of the Seven Minute Screen.
Laboratory tests were all normal. Baseline MRI showed mild 
diffuse atrophy of the cerebrum together with some small ves-
sel lesions affecting periventricular and semioval white matter. 
Follow-up MRI (5  years later) showed more intense atrophy 
in the left frontal and temporal lobes (Figure  1A). Tc-99m-
HMPAO SPECT showed bilateral but asymmetric hypoperfu-
sion (more on the left side) on frontotemporal lobes (Figure 1B). 
18F-FDG-PET showed mild to severe hypometabolism on the 
left frontotemporal lobe junction, and mild hypometabolism on 
the left fronto-basal left anterior cingulum regions (Figure 1C). 
DaTSPECT was informed as for the normal density of presyn-
aptic dopaminergic uptakers (Figure 1D). Some irregularities 
in the morphology of basal ganglia and increase of cortical 
uptake were present.
The final diagnosis was frontotemporal lobe dementia—
behavioral variant—with parkinsonism. Even when the density 
of presynaptic dopaminergic uptakers in the DaTSPECT was 
normal, she was put on Levodopa without significative clinical 
changes.
perspeCtiVe
Clinical observations
Parkinsonism is a well-known manifestation of FTLD (28). 
To date, presentations of FTLD with motor or movement dis-
orders include (1) frontal lobe degeneration (FTD) with motor 
neuron disease (FTD-MND), (2) corticobasal degeneration 
(CBD), and (3) progressive supranuclear palsy (PSP). CBS and 
PSP usually show parkinsonism. However, parkinsonism has 
also been reported as a relative finding in other subtypes of 
FTD apart from CBS and PSP. Indeed, parkinsonism is found 
in approximately 20–30% of patients with FTLD. Furthermore, 
parkinsonism can be seen in all FTLD subtypes, and it can even 
be an outstanding feature in some cases. Therefore, there is a 
need to investigate parkinsonism in FTLD to obtain a better 
understanding of the disease.
Regarding the clinical characteristics, features of parkinson-
ism in FTLD are variable. The classical akinetic-rigid syndrome 
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usually characterizes it. Other cases show atypical parkinsonism 
resembling PSP or CBD. Although rare, parkinsonism in FTLD 
may coexist with MND. Parkinsonism in FTLD is usually levodopa 
unresponsive, but there have been cases where a temporary 
benefit has been reported. The lack of response to levodopa 
reinforces the idea of a pathogenic mechanism different to PD.
genetics
A systematic review aimed at the characterization of movement 
disorder phenomenology in genetically proven familial FTLD, 
showed that at any point during the disease, parkinsonism 
was the most common movement syndrome. It was reported 
in 79.8% of cases, followed by PSP and CBD syndromes in 
12.2 and 10.7% of cases, respectively (28). The amyotrophic 
lateral sclerosis/parkinsonism dementia complex of Guam 
was probably the first known association of parkinsonism 
with dementia of frontotemporal features (29). Parkinsonism 
was frequently observed in familial FTLD, more specifically in 
FTLD with parkinsonism linked to chromosome 17q (FTDP-
17) (30). Parkinsonism in familial FTLD was first described 
in families with mutations in the microtubule-associated 
protein tau (MAPT) and progranulin (PRGN) genes. Since 
then, mutations in several other genes have been identified 
for FTLD with parkinsonism, including chromatin modifying 
protein 2B, chromosome 9 open reading frame 72 (C9ORF72), 
fused in sarcoma, valosin-containing protein, and transactive 
DNA-binding protein (TARDBP) (31, 32). Mutations in seven 
genes were robustly associated with autosomal dominant 
(SNCA, LRRK2, EIF4G1, VPS35) or recessive (parkin/PARK2, 
PINK1, DJ1/PARK7) PD or parkinsonism (33, 34). Changes 
in a long list of additional genes have also been suggested as 
causes for parkinsonism or PD, including genes for hereditary 
ataxias (ATXN2, ATXN3, FMR1), frontotemporal dementia 
(C9ORF72, GRN, MAPT, TARDBP), DYT5 (GCH1, TH, SPR), 
and others (ATP13A2, CSF1R, DNAJC6, FBXO, GIGYF2, 
HTRA2, PLA2G6, POLG, SPG11, UCHL1) (34–37).
neuropsychology and datspeCt  
imaging in pd and FtLd
Cognitive deficits could be identified in around a third of patients, 
even in the early untreated stages of PD (38–41). This cognitive 
dysfunction may have been related, in part, to reduced dopa-
mine levels. While there were some inconsistent findings in the 
literature (42), fMRI studies with patients on and off levodopa 
indicated that higher levels of dopamine were associated with 
better cognitive performances on tasks of working memory and 
response accuracy (43). In addition, recent fMRI and DaTSPECT 
research have demonstrated a positive correlation between 
nigrostriatal dopaminergic function and performance on tests 
of executive functioning and memory (44). However, dopamine 
deficiency may not explain all of the cognitive deficits in PD, as 
some degree of cognitive impairment was common in patients 
diagnosed with related movement disorders such as dystonia 
(45) and essential tremor (46), conditions that were not associ-
ated with dopaminergic deficiency on imaging (13, 27, 36). These 
patients usually had an abnormal DaTSPECT as the damage in 
frontostriatal neural circuitry occurred down (basal ganglia) to 
up (frontal cortex) (47).
It is a well-known fact that cognitive impairment in early PD 
and other synucleinopathies (Parkinson-plus syndromes) was 
accompanied by reductions in activity in frontostriatal neural 
circuitry (48, 49). There were five fronto-subcortical circuits link-
ing different regions of the frontal cortex and subcortical nuclei, 
involving several neurotransmitters. Nigrostriatal dopaminergic 
neurons played an important role in some of these circuits, but 
gabaergic, glutamatergic, and cholinergic neurons were also 
extensively represented. Therefore, neurodegenerative disorders 
affecting neurons outside the nigrostriatal dopaminergic circuits 
were not be detected by DaTSPECTs and would have still been 
able to produce extrapyramidal symptoms.
When dementia preceded PD, international consensus 
recommended a diagnosis of these patients with Dementia 
with Lewy bodies (DLB). Nevertheless, most patients with 
DLB and extrapyramidal signs had abnormal DaTSPECTs. In 
fact, autopsy studies provided class I evidence of 123I-FP-CIT 
dopaminergic neuroimaging accurately identifying patients 
with DLB (50), although this could be normal in those without 
extrapyramidal signs.
What is most relevant to the hypothesis presented in this 
paper is the fact that many SWEDD patients exhibited cognitive 
dysfunction. Studies with data from the Parkinson’s Progression 
Marker Initiative (PPMI) database, showed that SWEDD patients 
performed significantly worse in semantic fluency and process-
ing speed when compared with healthy controls (51). Montreal 
Cognitive Assessment test (MoCA) scores showed that about 
one-third of the PPMI participants were clinically diagnosed with 
SWEDD, experienced a statistically significant cognitive decline 
over the relatively brief period of 2 years, and a higher propor-
tion of participants with SWEDD than DaTSPECT-confirmed 
PD had cognitive decline. The participants in the SWEDD 
group were more than twice as likely (relative risk = 2.07) than 
those in the dopamine-deficient group to fall below the MoCA 
cognitive impairment cutoff. Thus, recently diagnosed patients 
with SWEDD may have been an even more significant risk for 
cognitive decline than patients with DaTSPECT-confirmed early-
stage PD (52, 53). Neuropsychological performances between the 
SWEDD and the PD resulted similar when comparing patients in 
all stages (54). Altogether, these results suggested that SWEDD 
should not be considered a benign finding, as a high proportion 
of patients could be expected to suffer a cognitive decline in the 
close future.
Some studies have shown decreased uptake of DaT in bilat-
eral putamina in FTLD with a negative correlation between the 
uptake ratio and parkinsonian motor status (55). Another study 
by Morgan and colleagues found that around a third of the FTLD 
cases may have presented abnormal scan and a significant reduc-
tion in uptake in the putamen and the caudate (56). Therefore, 
patients with FTLD may have had a positive or a negative 
DaTSPECT. This result probably depends on the neuropathology 
and clinical subtype of FTLD.
For instance, a study with patients with non-fluent/agram-
matic variant of primary progressive aphasia (nfvPPA) and a 
logopenic variant of PPA (lvPPA) without clinical parkinsonism 
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at baseline, showed reduced striatal tracer uptake in nfvPPA 
patients prior to clinical parkinsonism, especially for those 
nfvPPA without AD biomarkers, suggesting subclinical 
nigrostriatal degeneration (57). All lvPPA patients had nor-
mal DaTSPECT. Patients with nfvPPA presented abnormal 
DaTSPECT, especially in the left hemisphere compared with 
controls. DaTSPECT in nfvPPA patients with normal pro-
granulin and negative CSF AD biomarkers was also significantly 
reduced compared with lvPPA patients with positive CSF AD 
biomarkers, suggesting nigrostriatal degeneration does not 
usually appear in the context of AD pathology resent, but it can 
appear in the context of FTD patho logies. During follow-up, 
seven nfvPPA/bio-patients developed parkinsonism, six of 
them with baseline reduced 123I-FP-CIT uptake (57).
FinaL reMarKs
The literature shows many clinical, genetic, and neuropsychologi-
cal studies linking parkinsonism and FTLD. Also, a good number 
of articles provide evidence of the distinct characteristics between 
PD and SWEDD, and on the cognitive impairment present in 
many SWEDD cases. Finally, DaTSPECT studies in FTLD found 
both positive and negative results.
We report the case of a patient diagnosed with a behavioral 
variant of frontotemporal lobe dementia who also has parkinson-
ism that was not attributable to vascular lesions, antidopamin-
ergic drugs, or any other etiology. DaTSPECT was informed as 
normal, and therefore it might be considered SWEDD.
On this basis, we reinforce the observation that parkinsonism 
without evidence of nigrostriatal dopaminergic deficit can be 
present in FTLD patients. Even when most of them will also 
present cognitive impairment, parkinsonism may be the main 
reason for consultation, and a normal DaTSCAN can be found 
during the diagnostic process. Therefore, FTLD may account for 
a percentage of patients with SWEDD. This origin might contri-
bute to the observation that SWEDD patients exhibit a higher 
risk of cognitive impairment, worse mood, and better olfaction 
than PD patients (19, 51). Other causes of SWEDD have been 
described, particularly dysto nic tremor. Thus, SWEDD should 
be understood as a heterogeneous group of patients in which 
some cases (probably the most tremoric ones) may have dys-
tonic tremor, and some others may have FTLD (probably those 
with outstanding frontal cognitive dysfunction).
Careful clinical assessment remains the cornerstone of the 
study of patients with FTLD with parkinsonism. However, 
rationale support of genetic studies, neuropsychological evalu-
ation, and neuroimaging, including structural and functional 
techniques, will provide a more detailed and comprehensive 
picture.
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